Unknown PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT01602939

Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis

Subcutaneous Cladribine Plus Pegylated Interpheron Alfa-2a in Advanced Systemic Mastocytosis With D816V and Other Exon 17 KIT Mutations.

Sponsor: Hospital Virgen de la Salud

Conditions Systemic Mastocytosis

Interventions Cladribine and pegylated interpheron alpha-2a

Updated 6 times since 2017 Last updated: Aug 26, 2016 Started: May 31, 2012 Primary completion: Feb 28, 2017 Completion: Jun 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Systemic Mastocytosis and is currently ongoing. Hospital Virgen de la Salud leads this study, which shows 6 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2/PHASE3

Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2_PHASE3
Sep 2018 — Jan 2021 [monthly]

Unknown Status PHASE2_PHASE3

Status: Recruiting → Unknown Status
Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE2_PHASE3

First recorded

May 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hospital Virgen de la Salud

Data source: Hospital Virgen de la Salud

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toledo, Spain